Pharma News

Researchers found In the fight against bovine spongiform encephalopathy, the incurable brain-wasting disease also known as mad cow disease, a new drug compound could lead to a breakthrough.

Hetero Group, one of India’s leading generic pharmaceutical companies  has recently announced the launch of its biosimilar ‘Rituximab’ under the brand name Maball in India. It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero. Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths – 100mg/10ml and 500mg/50ml.

Dr Reddy's Laboratories has entered into a strategic collaboration with Amgen to market and distribute three Amgen medicines in India in the areas of oncology and cardiology. Under the terms of the collaboration, DRL will launch Kyprolis (carfilzomib), Blincyto (blinatumomab and Repatha (evolocumab) in India.

Many recommendations and guidelines on several aspects of infant care such as sleep position, breastfeeding, immunization and pacifier issued by Health care practitioner groups. Yet many new mothers do not follow this advice from physicians, revealed a new study. The study appears in the Pediatrics.

A new study says, drugs that are commonly used to treat gout may protect from alcohol-induced liver disease and inflammation. The study is published in Journal of Leukocyte Biology.

A chemical found in red grapes, Resveratrol, may help prevent bowel cancer, and is more effective if given in smaller doses, find scientists. The study is published in the journal Science Translational Medicine.

Ajanta Pharma Limited, a Rs.1,450 crore plus Mumbai based specialty focused pharmaceutical formulation company, has received final approval from the United States Food and Drug Administration (FDA)  for its 3 Abbreviated New Drug Applications (ANDAs), montelukast tablets, 10mg,  montelukast sodium chewable tablets, 4mg & 5mg and montelukast oral granules.